Pharmaceutical composition for preparing a medicine for treating and/or preventing a pathology related to an obsessive behaviour or obesity
CA 2503546 C · Owner: Universite De Nimes · Inventors: Compan, Valerie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns the use of a 5-HT¿4? receptor ligand or a pharmaceutically acceptable salt of said ligand and of a nucleic acid encoding a functional 5-HT¿4? receptor or a functionally equivalent receptor for preparing a medicine for treating and/or preventing a pathology related to an obsessive behaviour such as anorexia bulimia and abuse drug addiction or obesity. The invention also concerns a method for identifying a compound biologically active in the treatment and/or prevention of a pathology related to an obsessive behaviour or obesity characterized in that it comprises the following steps: (a) contacting the 5-HT¿4? receptor or a functionally equivalent receptor with said …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 31, 2003 and granted February 11, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 31, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 31, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.